drugset / Trial / NCT02300311
Efficacy and Safety of Finalgon® Cream Multiple Doses in Acute Low Back Pain
RandomizedParallel-groupDouble-blindTreatment
Summary
To evaluate efficacy of Finalgon® cream (1.08% Nicoboxil/ 0.17% Nonivamide) versus placebo in patients with acute low back pain. To investigate the safety and tolerability of repeated use of Finalgon® cream (1.08% Nicoboxil/ 0.17% Nonivamide).
Timeline
- Start
- 2015-01
- Primary completion
- 2015-05
- Completion
- 2015-05
Outcome
Met primary endpoint
registry Placebo vs Finalgon® Cream (Nicoboxil/ Nonivamide); p <0.0001; Mean Difference (Final Values) -1.849 (95% CI -2.454 to -1.244) NCT02300311 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | nicoboxil | Small molecule | 1.08 % | Topical |
| Subject | nonivamide | Small molecule | 0.17 % | Topical |
Indications
No indication recorded.